We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current MRNS market cap is 74.71M. The company's latest EPS is USD -2.5741 and P/E is -0.53.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.38M | 6.08M | 7.34M | 7.19M | 7.68M |
| Operating Income | -32.96M | -31.44M | -31.65M | -35.44M | -35.82M |
| Net Income | -34.73M | -31.93M | -32.97M | -41.77M | -38.67M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 1.72M | 15.35M | 25.48M | 30.99M |
| Operating Income | -54.42M | -67.94M | -96.93M | -112.79M | -131.49M |
| Net Income | -54.12M | -67.48M | -98.78M | -19.82M | -141.41M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 226.82M | 201.2M | 200.81M | 170.91M | 137.35M |
| Total Liabilities | 141.73M | 143.86M | 146.27M | 154.14M | 153.78M |
| Total Equity | 85.09M | 57.34M | 54.54M | 16.77M | -16.43M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 98.84M | 150.46M | 136.84M | 259.52M | 170.91M |
| Total Liabilities | 11.07M | 13.26M | 83.35M | 143.52M | 154.14M |
| Total Equity | 59.57M | 137.2M | 53.49M | 116M | 16.77M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -41.48M | -65.84M | -91.01M | -118M | -37.46M |
| Investing | -52M | -46.99M | -35.07M | -28.61M | 20.89M |
| Financing | -174k | 63k | 25.97M | 26.63M | 257k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -48.63M | -60.91M | -55.48M | -112.89M | -118M |
| Investing | 3.88M | -738k | -1.42M | 105.77M | -28.61M |
| Financing | 67.97M | 109.22M | 41.31M | 124.74M | 26.63M |
| Market Cap | 74.71M |
| Price to Earnings Ratio | -0.53 |
| Price to Sales Ratio | 2.41 |
| Price to Cash Ratio | 0.62 |
| Price to Book Ratio | 4.46 |
| Dividend Yield | - |
| Shares Outstanding | 54.93M |
| Average Volume (1 week) | 1.12M |
| Average Volume (1 Month) | 987.56k |
| 52 Week Change | -86.41% |
| 52 Week High | 11.26 |
| 52 Week Low | 1.11 |
| Spread (Intraday) | 0.04 (2.94%) |
| Company Name | Marinus Pharmaceuticals Inc |
| Address |
3411 silverside road tatnall building wilmington, delaware 19810 |
| Website | https://www.marinuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
